Compare ALEMBIC PHARMA with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs AUROBINDO PHARMA - Comparison Results

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA AUROBINDO PHARMA ALEMBIC PHARMA/
AUROBINDO PHARMA
 
P/E (TTM) x 15.7 16.8 93.2% View Chart
P/BV x 6.2 3.6 171.2% View Chart
Dividend Yield % 0.6 0.3 211.5%  

Financials

 ALEMBIC PHARMA   AUROBINDO PHARMA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-19
AUROBINDO PHARMA
Mar-19
ALEMBIC PHARMA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs664830 80.0%   
Low Rs412527 78.2%   
Sales per share (Unadj.) Rs208.7333.9 62.5%  
Earnings per share (Unadj.) Rs31.040.4 76.8%  
Cash flow per share (Unadj.) Rs37.151.8 71.7%  
Dividends per share (Unadj.) Rs5.502.50 220.0%  
Dividend yield (eoy) %1.00.4 277.4%  
Book value per share (Unadj.) Rs144.2237.1 60.8%  
Shares outstanding (eoy) m188.52585.91 32.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.62.0 126.9%   
Avg P/E ratio x17.416.8 103.3%  
P/CF ratio (eoy) x14.513.1 110.6%  
Price / Book Value ratio x3.72.9 130.4%  
Dividend payout %17.76.2 286.4%   
Avg Mkt Cap Rs m101,461397,569 25.5%   
No. of employees `000NA17.9 0.0%   
Total wages/salary Rs m7,46725,849 28.9%   
Avg. sales/employee Rs ThNM10,956.9-  
Avg. wages/employee Rs ThNM1,447.7-  
Avg. net profit/employee Rs ThNM1,324.3-  
INCOME DATA
Net Sales Rs m39,347195,636 20.1%  
Other income Rs m941,553 6.0%   
Total revenues Rs m39,441197,189 20.0%   
Gross profit Rs m8,73639,519 22.1%  
Depreciation Rs m1,1526,680 17.3%   
Interest Rs m1842,626 7.0%   
Profit before tax Rs m7,49331,767 23.6%   
Minority Interest Rs m1127 40.0%   
Prior Period Items Rs m-930-   
Extraordinary Inc (Exp) Rs m0-881 0.0%   
Tax Rs m1,5687,269 21.6%   
Profit after tax Rs m5,84423,645 24.7%  
Gross profit margin %22.220.2 109.9%  
Effective tax rate %20.922.9 91.4%   
Net profit margin %14.912.1 122.9%  
BALANCE SHEET DATA
Current assets Rs m19,577153,645 12.7%   
Current liabilities Rs m14,896120,429 12.4%   
Net working cap to sales %11.917.0 70.1%  
Current ratio x1.31.3 103.0%  
Inventory Days Days90135 66.4%  
Debtors Days Days4564 71.2%  
Net fixed assets Rs m27,097103,909 26.1%   
Share capital Rs m377586 64.3%   
"Free" reserves Rs m26,811138,322 19.4%   
Net worth Rs m27,188138,908 19.6%   
Long term debt Rs m4,9931,800 277.5%   
Total assets Rs m47,778264,544 18.1%  
Interest coverage x41.713.1 318.4%   
Debt to equity ratio x0.20 1,417.6%  
Sales to assets ratio x0.80.7 111.4%   
Return on assets %12.69.9 127.0%  
Return on equity %21.517.0 126.3%  
Return on capital %23.623.8 99.0%  
Exports to sales %049.6 0.0%   
Imports to sales %018.8 0.0%   
Exports (fob) Rs mNA97,091 0.0%   
Imports (cif) Rs mNA36,741 0.0%   
Fx inflow Rs m19,45397,316 20.0%   
Fx outflow Rs m6,06540,589 14.9%   
Net fx Rs m13,38856,727 23.6%   
CASH FLOW
From Operations Rs m8,12016,220 50.1%  
From Investments Rs m-7,556-28,768 26.3%  
From Financial Activity Rs m59019,191 3.1%  
Net Cashflow Rs m1,1536,656 17.3%  

Share Holding

Indian Promoters % 74.1 54.1 137.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 8.0 36.5%  
FIIs % 9.1 27.7 32.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 10.2 136.3%  
Shareholders   49,328 69,601 70.9%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  FULFORD INDIA  NATCO PHARMA  ELDER PHARMA  

Compare ALEMBIC PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 257 Points Higher, Coal India and UPL Among Top Gainers(Closing)

Indian share markets continued their positive trend during closing hours today and ended their day on a firm note.

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 13.8% (Quarterly Result Update)

Jan 19, 2021 | Updated on Jan 19, 2021

For the quarter ended December 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 13.8% YoY). Sales on the other hand came in at Rs 13 bn (up 8.7% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 30.0% (Quarterly Result Update)

Oct 23, 2020 | Updated on Oct 23, 2020

For the quarter ended September 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 30.0% YoY). Sales on the other hand came in at Rs 15 bn (up 17.4% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

Intraday Trading for a Living(Fast Profits Daily)

Feb 15, 2021

In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.

Penny Stock Master Series: The Quest for 10X Profits in 10 Years(Profit Hunter)

Feb 12, 2021

This is first of the three part master series. In these editorials, I'll show you how to earn 10X returns from a penny stock portfolio over 10 years.

Top 5 Stocks Mutual Funds Bought and Sold in January 2021(Sector Info)

Feb 16, 2021

A look at what India's top equity mutual funds bought and sold in January 2021.

I Would Recommend this Small-cap Stock Over Tesla(Profit Hunter)

Feb 16, 2021

Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Feb 25, 2021 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - GSK PHARMA COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS